Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

Xueyan Wang; Xiaowei Liu; Willy Hugo; Lu Si; Hubing Shi

doi:10.3389/fimmu.2022.1065937

Editorial: Improvement of melanoma immune checkpoint blockade therapy with potential combinatorial regiments

Front Immunol. 2022 Oct 31:13:1065937. doi: 10.3389/fimmu.2022.1065937. eCollection 2022.

Authors

Xueyan Wang¹, Xiaowei Liu¹, Willy Hugo², Lu Si³, Hubing Shi¹

Affiliations

¹ Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
² Division of Dermatology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, CA, United States.
³ Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Renal Cancer and Melanoma, Peking University Cancer Hospital and Institute, Beijing, China.

No abstract available

Keywords: biomarker; combination therapy; immune checkpoint blockade (ICB); immune checkpoint inhibitors (ICIs); immune-related adverse events (irAEs); melanoma.

Publication types

Editorial

MeSH terms

Humans
Immune Checkpoint Inhibitors* / therapeutic use
Melanoma*
Radioimmunotherapy

Substances

Immune Checkpoint Inhibitors

Grants and funding

R01 CA236910/CA/NCI NIH HHS/United States